<DOC>
	<DOCNO>NCT01991327</DOCNO>
	<brief_summary>The primary objective study ass drug-drug interaction Androxal cytochrome P450 isoenzymes , CYP1A2 , CYP2C8 , CYP2C9 , CYP2C19 , CYP2D6 , CYP3A4 healthy male subject administer 25 mg Androxal daily 3 day . Secondly , safety tolerability Androxal determine healthy male subject administer Androxal 25 mg daily 3 day .</brief_summary>
	<brief_title>Assessment Drug-Drug Interactions Androxal With Cytochrome P450 Isoenyzmes Healthy Males</brief_title>
	<detailed_description />
	<mesh_term>Enclomiphene</mesh_term>
	<mesh_term>Clomiphene</mesh_term>
	<mesh_term>Zuclomiphene</mesh_term>
	<criteria>Speak , read , understand English Spanish willing able provide write informed consent institutional review board ( IRB ) approve form prior initiation study procedure ; Healthy male , age 18 60 year ; body mass index ( BMI ) 19.029.9 . All laboratory test either within normal range assess clinically significant Principal Investigator . Any clinically significant deviation outside normal range opinion Principal Investigator require sponsor approval . A negative hepatitis B surface antigen , hepatitis C antibody HIV antibody test result within previous 3 month may use instead obtain screen laboratory sample laboratory test ; Ability complete study accordance protocol . Known hypersensitivity Clomid ; A clinically significant laboratory abnormality clinical finding indicative clinically significant exclusionary disease include hepatic insufficiency , renal insufficiency , unstable coronary artery disease , malignancy basal cell carcinoma squamous cell carcinoma skin stroke ; A positive hepatitis screen include hepatitis surface B antigen ( HBsAg ) hepatitis C antibody ; A positive test result HIV ; Positive result urine screen substance abuse ; A recent history alcoholism ( &lt; 2 year ) moderate alcohol use ( great average 3 drink per day total 21 drink per week ) use alcohol within 24 hour prior receive first dose study medication ; Use recreational drug within past year previous history drug abuse ; Use investigational drug product , participation drug research study within 30 day prior receive study medication ; A clinically significant electrocardiogram ( ECG ) abnormality ; A history difficulty phlebotomy ; Donation blood ( 1 pint ) within 30 day , plasma within 7 day prior receive study medication ; Use prescription drug therapy within 14 day prior receive study medication ; Use overthecounter ( OTC ) drug therapeutic purpose within 48 hour prior receive study medication ; Use dietary herbal supplement 14 day prior study megavitamin supplement within 48 hour prior receive study medication ; Consumption caffeine contain food beverage within 48 hour prior receive study medication ; Consumption grapefruit grapefruitcontaining juice , vegetable mustard green family , charbroiled meat within 72 hour prior receive study medication ; Current smoker user tobacco product smoke last 30 60 day ; Any condition , opinion Principal Investigator , could interfere subject 's ability provide inform consent , comply study instruction , possibly confound interpretation study result , endanger subject take part study ; Classified cytochrome P450 isoenzyme 2D6 ( CYP2D6 ) `` poor metabolizer '' determine genotyping screen visit Use monoamine oxidase ( MAO ) Inhibitor previous 28 day prior dose . Concurrent use cimetidine , levodopa , amantadine , antipsychotic antidepressant . Type I Type II diabetes Clinical evidence cirrhosis biopsy proven cirrhosis etiology Screening liver function test ( ALT , AST , Bil , Alk . Phos ) great upper limit normal History hypertension BP &gt; 150/95 mmHg seat screen History chronic pancreatitis cholelithiasis</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>